Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human endostatin adenovirus plus chemotherapy vs paclitaxel + cisplatin in head and neck squamous cell carcinoma
CTR20150683Phase 3Completed
- Sponsor
- Guangzhou Doublle Bioproduct Co., Ltd.
- Start
- Dec 2020
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Recombinant human endostatin adenovirus in head and neck squamous cell carcinoma (HNSCC), sponsored by Guangzhou Doublle Bioproduct Co., Ltd.. Started Dec 2020; status: completed.
02
Drugs
Recombinant human endostatin adenovirus
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20150683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150683.